title: MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
abstract: The gastrin-releasing peptide receptor (GRPR) is overexpressed on a variety of carcinomas and has been the target for detection and treatment of these neoplasms in animals. In particular, analogues of the tetradecapeptide bombesin (BN) have been radiolabeled with (99m)Tc and (111)In for detection of GRPR-positive tumors by gamma ray scintigraphy. The goal of this study was to evaluate the potential of the bombesin analogue, DOTA-Aoc-BN(7-14), for positron-emission tomographic (PET) imaging after radiolabeling with the positron-emitter (64)Cu. A saturation binding assay on PC-3 human prostate cancer cells showed that (64)Cu-DOTA-Aoc-BN(7-14) had an equilibrium binding constant (K(d)) of 6.1 +/- 2.5 nM and a receptor concentration (B(max)) of 2.7 +/- 0.6 x 10(5) receptors/cell. The radiolabeled analogue also showed rapid internalization with 18.2% internalized into 10(5) PC-3 cells by 2 h. The tumor localization of (64)Cu-DOTA-Aoc-BN(7-14) was 5.5% injected dose per gram in athymic nude mice bearing PC-3 xenografts at 2 h postinjection. The tumor retention with respect to the 2 h value was 76% and 45% at 4 and 24 h, respectively, and was GRPR-mediated as shown by inhibition with a coinjection of excess peptide. MicroPET imaging of (64)Cu-DOTA-Aoc-BN(7-14) in athymic nude mice bearing subcutaneous PC-3 tumors showed good tumor localization. Further studies with (64)Cu-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) ((64)Cu-PTSM) suggested that low blood flow to the PC-3 tumors may have limited the localization of (64)Cu-DOTA-Aoc-BN(7-14). This study demonstrates that (64)Cu-DOTA-Aoc-BN(7-14) can be used to detect GRPR-positive tumors by PET imaging.
authors.affiliation: Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. rogers@radonc.wustl.edu
authors.forename: Buck E
authors.initials: BE
authors.lastname: Rogers
authors.forename: Heather M
authors.initials: HM
authors.lastname: Bigott
authors.forename: Deborah W
authors.initials: DW
authors.lastname: McCarthy
authors.forename: Debbie
authors.initials: D
authors.lastname: Della Manna
authors.forename: Joonyoung
authors.initials: J
authors.lastname: Kim
authors.forename: Terry L
authors.initials: TL
authors.lastname: Sharp
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Welch
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D001783:Blood Flow Velocity / Q000502:physiology; D001839:Bombesin / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D003301:Copper Radioisotopes; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D023421:Models, Animal; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D018004:Receptors, Bombesin / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D003301:Copper Radioisotopes; D018004:Receptors, Bombesin; D001839:Bombesin